2014Oncology TimesRequires access

How to Pay for Cancer Care

Lola Butcher

Open publisher page 0 citations

Abstract

FigureCancer care providers—and payers—agree that a new way for paying for cancer treatment and follow-up monitoring must be found, but exactly what that new pay system should be remains unclear. The American Society of Clinical Oncology and the Community Oncology Alliance are advancing the discussion by jointly issuing a set of payment reform principles. They agree with everyone else that Medicare's current system—paying the average sales price for cancer drugs plus six percent—is insufficient to cover the costs of most oncology practices and it does nothing to differentiate between physicians who provide high-quality care and those who do not. The joint principles include: Oncology professionals should take a lead in developing new care models, which must promote access to evidence-based care, improve quality, and help control costs. Changing to new care models requires significant expense, time, and effort so changes in payment models should be incremental over a period of time. Oncology providers should be protected against new pay policies that will undermine their ability to invest in their practice changes. Quality measures should play an important role in evaluating and paying oncology providers. One-size-fits-all may not apply to oncology delivery or pay models. Rather, providers should be able to choose the approach that fits best in their community. Indeed, ASCO and COA each has its own proposal for cancer care payment reform. ASCO wants to see monthly payments for cancer care in which the payment amount reflects the particular stage of care, such as treatment, non-treatment and transition of treatment. Additionally, ASCO proposes additional compensation for performance on quality measures, adherence to cancer care pathways, management of patient care that reduces emergency and inpatient care, and participation in clinical trials. Meanwhile, COA is promoting a pay system that would support its Oncology Medical Home practice model. Its concept, which would be phased in over five years, would gradually replace fee-for-service with episode-of-care payment and shared savings that reward clinicians for high- quality care delivered at the lowest possible cost. Do either of these proposals sound feasible? Please let me know—tweet me at @LolaButcher, or email [email protected]

About this research paper

What this paper is about

FigureCancer care providers—and payers—agree that a new way for paying for cancer treatment and follow-up monitoring must be found, but exactly what that new pay system should be remains unclear. The American Society of Clinical Oncology and the Community Oncology Alliance are advancing the discussion by jointly issuing a set of payment reform principles. They agree with everyone else that Medicare's current system—paying the average sales price for cancer drugs plus six percent—is insufficient to cover the costs of most oncology practices and it does nothing to differentiate between physicians who provide high-quality care and those who do not. The joint principles include: Oncology professionals should take a lead in developing new care models, which must promote access to evidence-based care, improve quality, and help control costs. Changing to new care models requires significant expense, time, and effort so changes in payment models should be incremental over a period of time. Oncology providers should be protected against new pay policies that will undermine their ability to invest in their practice changes. Quality measures should play an important role in evaluating and paying oncology providers. One-size-fits-all may not apply to oncology delivery or pay models. Rather, providers should be able to choose the approach that fits best in their community. Indeed, ASCO and COA each has its own proposal for cancer care payment reform. ASCO wants to see monthly payments for cancer care in which the payment amount reflects the particular stage of care, such as treatment, non-treatment and transition of treatment. Additionally, ASCO proposes additional compensation for performance on quality measures, adherence to cancer care pathways, management of patient care that reduces emergency and inpatient care, and participation in clinical trials. Meanwhile, COA is promoting a pay system that would support its Oncology Medical Home practice model. Its concept, which would be phased in over five years, would gradually replace fee-for-service with episode-of-care payment and shared savings that reward clinicians for high- quality care delivered at the lowest possible cost. Do either of these proposals sound feasible? Please let me know—tweet me at @LolaButcher, or email [email protected]

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

FigureCancer care providers—and payers—agree that a new way for paying for cancer treatment and follow-up monitoring must be found, but exactly what that new pay system should be remains unclear. The American Society of Clinical Oncology and the Community Oncology Alliance are advancing the discussion by jointly issuing a set of payment reform principles. They agree with everyone else that Medicare's current system—paying the average sales price for cancer drugs plus six percent—is insufficient to cover the costs of most oncology practices and it does nothing to differentiate between physicians who provide high-quality care and those who do not. The joint principles include: Oncology professionals should take a lead in developing new care models, which must promote access to evidence-based care, improve quality, and help control costs. Changing to new care models requires significant expense, time, and effort so changes in payment models should be incremental over a period of time. Oncology providers should be protected against new pay policies that will undermine their ability to invest in their practice changes. Quality measures should play an important role in evaluating and paying oncology providers. One-size-fits-all may not apply to oncology delivery or pay models. Rather, providers should be able to choose the approach that fits best in their community. Indeed, ASCO and COA each has its own proposal for cancer care payment reform. ASCO wants to see monthly payments for cancer care in which the payment amount reflects the particular stage of care, such as treatment, non-treatment and transition of treatment. Additionally, ASCO proposes additional compensation for performance on quality measures, adherence to cancer care pathways, management of patient care that reduces emergency and inpatient care, and participation in clinical trials. Meanwhile, COA is promoting a pay system that would support its Oncology Medical Home practice model. Its concept, which would be phased in over five years, would gradually replace fee-for-service with episode-of-care payment and shared savings that reward clinicians for high- quality care delivered at the lowest possible cost. Do either of these proposals sound feasible? Please let me know—tweet me at @LolaButcher, or email [email protected]

Key concepts: Payment, Quality (philosophy), Reimbursement, Business, Set (abstract data type), Alliance, Oncology, Actuarial science

Related papers

Back to paper searchBrowse research topicsOriginal source
How to Pay for Cancer Care — Research Paper | ScholarLens